GLP-1
Incretin Hormone & Insulin Secretion Regulation
What is GLP-1?
GLP-1 (glucagon-like peptide-1) is a 30-amino-acid incretin hormone secreted by intestinal L-cells in response to nutrient intake. On this reference site, the GLP-1 research peptide corresponds to the semaglutide sequence — a long-acting GLP-1 receptor agonist engineered for resistance to enzymatic degradation. Its core mechanism is activation of the GLP-1 receptor, which stimulates glucose-dependent insulin secretion from pancreatic beta-cells, suppresses glucagon release to reduce hepatic glucose output, and slows gastric emptying. Research also indicates the peptide acts on central nervous system pathways involved in appetite regulation, promoting satiety and reducing caloric intake.
It is important to distinguish the underlying reference drug from the research compound sold here. Semaglutide itself is an approved medicine used clinically for type 2 diabetes and chronic weight management, and large randomized clinical trials have been foundational to understanding this drug class. In those trials, GLP-1 receptor agonism has been associated with meaningful average weight reduction — figures in the range of roughly 15% of body weight have been reported for semaglutide in higher-dose weight-management studies, alongside improvements in glycemic markers. Preclinical work has additionally explored neuroprotective and cardiometabolic effects, though these remain areas of ongoing investigation rather than settled conclusions.
Research continues to characterize the broader physiology of GLP-1 signaling, including its effects on inflammation, cardiovascular endpoints, and the durability of metabolic changes over time. What the literature consistently suggests is that GLP-1 receptor agonism represents one of the most extensively studied mechanisms in modern metabolic science. The peptide offered here, however, is not the approved pharmaceutical formulation and is intended strictly for research and educational purposes only — it is not approved for human use and no statements here should be interpreted as medical guidance.
Molecular data
Mechanism of action
In preclinical research, GLP-1 is associated with the following pathways and targets:
Research highlights
- Stimulates glucose-dependent insulin secretion from pancreatic β-cells
- Suppresses glucagon release, reducing hepatic glucose output
- Slows gastric emptying, promoting satiety and reducing caloric intake
- Neuroprotective effects observed in preclinical CNS models
Frequently asked questions
What is GLP-1 and how does it work?
GLP-1 is an incretin hormone that activates the GLP-1 receptor. Research indicates it stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on appetite-regulating brain pathways to promote satiety.
Is the GLP-1 peptide the same as semaglutide?
On this site the GLP-1 research peptide corresponds to the semaglutide sequence. Semaglutide is an approved medicine in clinical settings, but the research peptide sold here is not an approved pharmaceutical product and is intended for laboratory research only.
How much weight loss has been observed in GLP-1 studies?
In semaglutide weight-management clinical trials, average reductions of roughly 15% of body weight have been reported at higher doses. These figures describe the approved drug in supervised trials, not the research compound offered here.
How is GLP-1 different from dual and triple agonists?
GLP-1 agonists act on a single receptor. Dual agonists like the tirzepatide-class compound add GIP receptor activity, and triple agonists like the retatrutide-class compound add glucagon receptor activity, which trials suggest may increase metabolic effect.
Is this GLP-1 peptide approved for human use?
No. While semaglutide as a drug is approved for clinical use, the GLP-1 research peptide sold here is strictly for research and educational purposes and is not approved for human consumption.
Source GLP-1 at Purgo Labs
≥99% purity, third-party COA verification, and same-day fulfillment.
Shop GLP-1 at Purgo Labs ↗Related compounds
For research and educational purposes only. GLP-1 is not approved for human use by any regulatory authority, and nothing on this page constitutes medical advice, diagnosis, or treatment. Research findings referenced here are predominantly preclinical.